Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study.
Axial spondyloarthritis
Biomarker
Cardiovascular risk
Polymorphism
Subclinical atherosclerosis
Vaspin
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
13 04 2021
13 04 2021
Historique:
received:
19
01
2021
accepted:
31
03
2021
entrez:
14
4
2021
pubmed:
15
4
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Vaspin is a novel anti-inflammatory adipokine associated with cardiovascular (CV) disease and inflammation in chronic inflammatory conditions different from axial spondyloarthritis (axSpA). Given the high incidence of CV disease (mainly due to accelerated atherosclerosis) exhibited by axSpA patients, we wondered if vaspin could also be a key molecule in this process. However, data on the role of vaspin regarding atherosclerotic disease in the context of axSpA is scarce. For this reason, we aimed to evaluate the implication of vaspin, at the genetic and serological level, in subclinical atherosclerosis and CV risk in axSpA. This study included 510 patients diagnosed with axSpA. Carotid ultrasound (US) was performed to evaluate the presence of subclinical atherosclerosis. Three vaspin gene variants (rs2236242, rs7159023, and rs35262691) were genotyped by TaqMan probes. Serum vaspin levels were assessed by enzyme-linked immunosorbent assay. Statistical analysis was performed using STATA® v.11.1. Serum vaspin levels were significantly higher in female patients than in males and also in obese patients when compared to those with normal weight (p < 0.05). At the genetic level, we disclosed that the minor allele of rs2236242 (A) was associated with lower serum vaspin levels in axSpA, while the rs7159023 minor allele (A) was linked to higher serum levels (p < 0.05). When the three polymorphisms assessed were combined conforming haplotypes, we disclosed that the TGC haplotype related to high serum levels of vaspin (p = 0.01). However, no statistically significant association was observed between vaspin and markers of subclinical atherosclerosis, both at the genetic and serological level. Our results revealed that vaspin is linked to CV risk factors that may influence on the atherosclerotic process in axSpA. Additionally, we disclosed that serum vaspin concentration is genetically modulated in a large cohort of patients with axSpA.
Sections du résumé
BACKGROUND
Vaspin is a novel anti-inflammatory adipokine associated with cardiovascular (CV) disease and inflammation in chronic inflammatory conditions different from axial spondyloarthritis (axSpA). Given the high incidence of CV disease (mainly due to accelerated atherosclerosis) exhibited by axSpA patients, we wondered if vaspin could also be a key molecule in this process. However, data on the role of vaspin regarding atherosclerotic disease in the context of axSpA is scarce. For this reason, we aimed to evaluate the implication of vaspin, at the genetic and serological level, in subclinical atherosclerosis and CV risk in axSpA.
METHODS
This study included 510 patients diagnosed with axSpA. Carotid ultrasound (US) was performed to evaluate the presence of subclinical atherosclerosis. Three vaspin gene variants (rs2236242, rs7159023, and rs35262691) were genotyped by TaqMan probes. Serum vaspin levels were assessed by enzyme-linked immunosorbent assay. Statistical analysis was performed using STATA® v.11.1.
RESULTS
Serum vaspin levels were significantly higher in female patients than in males and also in obese patients when compared to those with normal weight (p < 0.05). At the genetic level, we disclosed that the minor allele of rs2236242 (A) was associated with lower serum vaspin levels in axSpA, while the rs7159023 minor allele (A) was linked to higher serum levels (p < 0.05). When the three polymorphisms assessed were combined conforming haplotypes, we disclosed that the TGC haplotype related to high serum levels of vaspin (p = 0.01). However, no statistically significant association was observed between vaspin and markers of subclinical atherosclerosis, both at the genetic and serological level.
CONCLUSIONS
Our results revealed that vaspin is linked to CV risk factors that may influence on the atherosclerotic process in axSpA. Additionally, we disclosed that serum vaspin concentration is genetically modulated in a large cohort of patients with axSpA.
Identifiants
pubmed: 33849644
doi: 10.1186/s13075-021-02499-7
pii: 10.1186/s13075-021-02499-7
pmc: PMC8042971
doi:
Substances chimiques
SERPINA12 protein, human
0
Serpins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111Références
Int J Mol Sci. 2018 Jun 11;19(6):
pubmed: 29891806
Gene. 2017 Aug 30;626:140-148
pubmed: 28479386
Eur J Endocrinol. 2010 Mar;162(3):507-13
pubmed: 19952124
Diabetes Metab J. 2014 Apr;38(2):143-9
pubmed: 24851208
Braz J Med Biol Res. 2016 Jul 4;49(7):
pubmed: 27383120
Cardiovasc Diabetol. 2018 May 30;17(1):75
pubmed: 29848323
Atherosclerosis. 2009 May;204(1):262-6
pubmed: 18848328
Diabetes Metab Syndr. 2018 Sep;12(5):643-648
pubmed: 29673927
Ann Rheum Dis. 2009 Jun;68 Suppl 2:ii1-44
pubmed: 19433414
Sci Rep. 2020 Jun 15;10(1):9636
pubmed: 32541676
Clin Exp Rheumatol. 2013 Jul-Aug;31(4):612-20
pubmed: 23406817
Clin Exp Rheumatol. 2018 Mar-Apr;36(2):302-309
pubmed: 29303699
Best Pract Res Clin Rheumatol. 2016 Oct;30(5):851-869
pubmed: 27964792
Sci Rep. 2018 Sep 13;8(1):13728
pubmed: 30213986
Annu Rev Med. 2005;56:303-20
pubmed: 15660514
Ann Rheum Dis. 2010 Jul;69(7):1410-1
pubmed: 19914904
Clin Exp Rheumatol. 2015 May-Jun;33(3):315-20
pubmed: 26005760
Eur J Appl Physiol. 2010 Jan;108(2):347-53
pubmed: 19816707
Joint Bone Spine. 2014 Jan;81(1):57-63
pubmed: 23731637
Clin Endocrinol (Oxf). 2011 Nov;75(5):628-35
pubmed: 21545478
J Int Med Res. 2012;40(5):1670-6
pubmed: 23206449
Int J Mol Sci. 2019 Aug 22;20(17):
pubmed: 31443349
Biomed Res Int. 2014;2014:860651
pubmed: 24757680
Diabetes. 2008 Feb;57(2):372-7
pubmed: 17991760
Int J Obes (Lond). 2013 Jun;37(6):861-6
pubmed: 22907691
J Clin Endocrinol Metab. 2012 Jul;97(7):E1202-7
pubmed: 22539588
Inflammation. 2013 Aug;36(4):914-20
pubmed: 23467997
Adv Exp Med Biol. 2019;1111:159-188
pubmed: 30051323
Diabetes Res Clin Pract. 2014 Oct;106(1):88-94
pubmed: 25151227
Int J Mol Sci. 2017 Aug 15;18(8):
pubmed: 28809783
Clin Chim Acta. 2013 Jan 16;415:233-8
pubmed: 23123830
Front Med (Lausanne). 2018 Mar 12;5:62
pubmed: 29594122
Diabetes. 2008 Jun;57(6):1501-7
pubmed: 18375437
Medicine (Baltimore). 2009 Nov;88(6):358-365
pubmed: 19910750
Arch Med Res. 2010 Aug;41(6):457-63
pubmed: 21044750
Atherosclerosis. 2014 Mar;233(1):248-52
pubmed: 24529152